Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.47 |
| ▸ | GSK3B | P49841 | 6/20 | 0.47 |
| ▸ | WNT1 | P04628 | 3/20 | 0.47 |
| ▸ | CLK2 | P49760 | 2/20 | 0.46 |
| ▸ | CLK3 | P49761 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20227781 | 0.85 | DYRK1A (0.58) | ABL1DYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL19307114 | 0.75 | ABL1 (0.48) | ABL1DYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL29614806 | 0.75 | ABL1 (0.48) | ABL1DYRK1AGSK3BWNT1CLK2 | |
| Cyclopropane SCHEMBL18887392 | 0.72 | ABL1 (0.74) | ABL1 | |
| SCHEMBL19515904 | 0.70 | GSK3B (0.78) | ABL1DYRK1AGSK3BWNT1CLK2 | |
| Cyclopropane SCHEMBL18887390 | 0.69 | ABL1 (0.73) | ABL1 | |
| SCHEMBL9941991 | 0.69 | ABL1 (0.84) | ABL1 | |
| SCHEMBL20214459 | 0.69 | ABL1 (0.69) | ABL1 | |
| SCHEMBL29614732 | 0.68 | PIK3CG (0.44) | ABL1 | |
| SCHEMBL19307151 | 0.68 | PIK3CG (0.44) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3548476-A1 | IRE1 SMALL MOLECULE INHIBITORS | Quentis Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018102751-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934275-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | ABL1 1855/4885DYRK1A 3563/4885GSK3B 2511/4885 |
| US-20190276434-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | ABL1 1855/4885DYRK1A 3563/4885GSK3B 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.